they can’t enrol n the trial unless they are eligible (which means failing at least one prior line of therapy). Also CORE NK is not yet FDA approved.
that said, early signals are very encouraging and the low toxicity profile is also very good.
one of the other CHM trials (Advent AML) which is specifically focused on AML as a first line therapy albeit with a different combo and eligbility criteria (patients who aren’t suitable for stem cell therapy) will have enrolled many more patients than the case western trial. Keen to see the prelim data!!
they can’t enrol n the trial unless they are eligible (which...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $69.79K | 17.44M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 40 | 26298938 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 9548289 | 12 |
View Market Depth
| Last trade - 16.10pm 18/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |